The tweet was deleted by the author.
But we saved everything 🙂.
AbbVie unveiled its Q3 2026 financial results in a company video update. The stock is up 1.7% on the day at $290.97.
AbbVie shared a video highlighting its Q3 2026 financial results, displaying its logo and animated performance graphs. The company is followed by 122 analysts, of whom 97 rate the stock a buy and 4 recommend selling. AbbVie operates in the general drug manufacturing sector, employs around 57,000 people, and holds a market value close to $488.55 billion on trailing revenue of $64.38 billion.
View post on X Loading...
AbbVie stock opened the session with a gap up from the prior close, jumping from $285.99 to $291 before retracing some of that initial advance. The underlying trend remains bullish, with price holding above its MA-20, MA-50, and MA-200 levels. Continued strength is suggested by alignment with the broader bullish daily chart structure, but RSI at 67.4 indicates the advance is beginning to look stretched as it moves near overbought territory. The nearest resistance is the weekly high at $292.67.
To gauge whether the latest news is being incorporated, traders should watch for a close above the weekly high at $292.67. The stock opened sharply higher, jumping from $285.99 to $291, before pulling back from those early gains. From here, the probability of further upside over the next five trading days is more than 80%, with downside risk less than 20% and an expected trading range from $285.85 to $296.08. A close above the weekly high would indicate buyers are ready to extend the rally, while a drop below $281.23 would suggest the move is losing traction. On the weekly chart, the longer-term picture remains firmly constructive.
Earlier, analysts noted that AbbVie's bullish technical structure persisted as investors anticipated its quarterly results. The latest video update confirming Q3 2026 results adds a new catalyst, with a close above the weekly high at $292.67 now serving as the key level to signal continued upside momentum.